Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Affiliations

• ¹ Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, University of Florence, Italy.
• ² Fondazione per la Ricerca Ospedale Maggiore (FROM), Papa Giovanni XXIII Hospital, Bergamo, Italy.
• ³ Hematology, Aziende Socio Sanitarie Territoriali (ASST) Sette Laghi, University of Insubria, Varese, Italy.
• ⁴ Division of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
• ⁵ Department of Hematology, Hospital, Clinic de Barcelona, Barcelona, Spain.
• ⁶ Department of Oncology-Hematology, University of Milan and Papa Giovanni XXIII Hospital, Bergamo, Italy.
• ⁷ Division of Hematology, NU Hospital Group, Uddevalla, Sweden; and.
• ⁸ Center of Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.